I will be talking with my hepatologist next Friday about a clinical trial he will be conducting. All I know is the drug is from France. He says he is very encouraged with their results so far. I have a few questions for him, but I’m hoping some of you who have been in trials might help me with a few questions to ask. I know I would have to be off Ocaliva for 3 months. Not too keen about being without my drug that long. Any help will be appreciated.
Thanks
Gail
Written by
gwillistexas
To view profiles and participate in discussions please or .
It may help prompt questions. I guess if it were me and I was given the placebo, I’d want to know if there would come a point when I’d be put back on medication, if there were any worsening of my bloods from being off OCA. Hope all goes well.
I understand that the drug Rifampicin is not so effective when it is restarted after stopping. I would want to know if Ocaliva has that same effect or if there are any other known side effects for stopping ocaliva and starting again. What if you end up in the placebo group what are the disbenefits to your liver. Having raised the points contarily being part of clinical research is an amazing thing to do for you and the wider community . Let us know how you do.
So, I have wondered how being off ocaliva would affect my liver. At this point we’re not sure it is helping me. When he discussed the biopsy results, I asked if he thought it wasn’t working. He said it could be that I am one who progress faster naturally, so it isn’t necessarily ocaliva not working. I feel like I’m in a round room looking for a corner. Ocaliva is my only option for now.
With the failure, elafibranor joins a number of other experimental drugs that have been unable to crack through and achieve regulatory victory in NASH, a metabolic liver disease estimated to affect more than 16 million people in the U.S. alone. Last month, the FDA issued a Complete Response Letter to Intercept Pharmaceuticals for its NASH treatment, obeticholic acid.
GENFIT said the decision to terminate the Phase III study is the first step of a new corporate strategy that includesa renewed focus on developing elafibranor in primary biliary cholangitis (PBC), a chronic, autoimmune disease in which bile ducts in the liver are gradually destroyed. The company called PBC “an exciting opportunity” as the market is expected to reach $1.5 billion by 2035 and remains an area of high, unmet need. Elafibranor showed promising results in a Phase II clinical trial for PBC and was granted Breakthrough Therapy designation by the U.S. Food and Drug Administration for this indication. GENFIT’s clinical team is focused on the launch of a Phase III study.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.